1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,418 | 0,479 | 08.01. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.12.25 | Cantargia Provides Update on Overall Survival Data from TRIFOUR | 179 | ACCESS Newswire | LUND, SE / ACCESS Newswire / December 5, 2025 / Cantargia (STO:CANTA) - Cantargia AB (Publ) (NASDAQ:CANTA.ST) today announced an update on overall survival results from the Phase 1b/2 TRIFOUR study... ► Artikel lesen | |
| 19.11.25 | Cantargia Q3 2025: Erster Gewinn durch transformativen Otsuka-Deal | 3 | Investing.com Deutsch | ||
| 19.11.25 | Cantargia Q3 2025 slides: First-ever profit driven by transformational Otsuka deal | 4 | Investing.com | ||
| 19.11.25 | Earnings Call Transkript: Cantargia meldet im 3. Quartal 2025 erstmals Umsatzerlöse | 2 | Investing.com Deutsch | ||
| 19.11.25 | Cantargia Publishes Interim Report for January to September 2025 | 259 | ACCESS Newswire | LUND, SE / ACCESS Newswire / November 19, 2025 / Cantargia AB (publ) ("Cantargia") (STO:CANTA) issued its interim report for the period January until September 2025. The report is now available on the... ► Artikel lesen | |
| 12.11.25 | Cantargia Presents Nomination Committee Ahead of 2026 AGM | 252 | ACCESS Newswire | LUND, SE / ACCESS Newswire / November 12, 2025 / Cantargia (STO:CANTA) - Cantargia AB (publ) (Nasdaq Stockholm:CANTA) today provided notification that the Nomination Committee (NC) has been appointed... ► Artikel lesen | |
| CANTARGIA Aktie jetzt für 0€ handeln | |||||
| 05.11.25 | Invitation to the Presentation of Cantargia's Interim Report January-September 2025 | 231 | ACCESS Newswire | LUND, SE / ACCESS Newswire / November 5, 2025 / Cantargia (STO:CANTA) - Cantargia AB (publ) (Nasdaq Stockholm:CANTA) will publish the company's interim report for the first nine months of 2025 on Wednesday... ► Artikel lesen | |
| 23.10.25 | Cantargia to Participate in Upcoming Conferences | 248 | ACCESS Newswire | LUND, SE / ACCESS Newswire / October 23, 2025 / Cantargia AB (publ) (Nasdaq Stockholm:CANTA)(STO:CANTA) today announced that management will participate in the following investor conferences.Stifel... ► Artikel lesen | |
| 02.10.25 | Cantargia Appoints Dr. Wolfram Dempke As Chief Medical Officer | 275 | ACCESS Newswire | LUND, SE / ACCESS Newswire / October 2, 2025 / Cantargia (STO:CANTA) - Cantargia AB (publ) (Nasdaq Stockholm: CANTA) today announced the appointment of Wolfram Dempke, MD, PhD, MBA as Chief Medical... ► Artikel lesen | |
| 01.10.25 | Cantargia Presents Data at an AACR Conference Strengthening IL1RAP as a Targetable Hallmark in PDAC | 377 | ACCESS Newswire | LUND, SE / ACCESS Newswire / September 30, 2025 / Cantargia (STO:CANTA)High IL1RAP protein expression on tumor cells is linked to poor survival in PDAC patients treated with chemotherapy, while this... ► Artikel lesen | |
| 11.09.25 | Cantargia Closes the Acquisition of CAN10 by Otsuka | 362 | ACCESS Newswire | LUND, SE / ACCESS Newswire / September 11, 2025 / Cantargia AB (publ) (Nasdaq Stockholm:CANTA) today announced that Cantargia and its partner Otsuka Pharmaceutical Co., Ltd. (Otsuka) have closed Otsuka's... ► Artikel lesen | |
| 29.08.25 | Cantargia im Q2 2025: Otsuka-Deal bringt 33 Mio. USD Sofortzahlung bei durchwachsenen klinischen Ergebnissen | 6 | Investing.com Deutsch | ||
| 29.08.25 | Cantargia Q2 2025 slides: Otsuka deal brings $33M upfront amid mixed clinical results | 2 | Investing.com | ||
| 27.08.25 | Cantargia Granted Important US Patent for Nadunolimab | 297 | ACCESS Newswire | LUND, SE / ACCESS Newswire / August 27, 2025 / Cantargia AB (Publ), Nasdaq Stockholm:CANTA, (Cantargia) today announced that the United States Patent and Trademark Office (USPTO) has granted the patent... ► Artikel lesen | |
| 21.08.25 | Cantargia: Aktie gibt trotz 630-Mio.-Dollar-Deal mit Otsuka nach | 5 | Investing.com Deutsch | ||
| 21.08.25 | Cantargia Publishes Half-Year Report 2025 | 385 | ACCESS Newswire | LUND, SE / ACCESS Newswire / August 21, 2025 / Cantargia AB (publ) [Nasdaq Stockholm:CANTA] (Cantargia) today issued the interim report for January to June 2025."I started my tenure as interim CEO with... ► Artikel lesen | |
| 18.08.25 | Cantargia Appoints Dr Hilde Steineger as Chief Executive Officer | 423 | ACCESS Newswire | Dr Steineger's appointment will be effective from September 1.She brings extensive experience as a biotech executive, with a proven track record spanning financial analysis, venture capital, and business... ► Artikel lesen | |
| 12.08.25 | Invitation to the Presentation of Cantargia's H1 2025 Report | 313 | ACCESS Newswire | LUND, SE / ACCESS Newswire / August 12, 2025 / Cantargia (Cantargia AB (publ); Nasdaq Stockholm:CANTA) will publish the company's interim report for the first six months of 2025 on Thursday, August... ► Artikel lesen | |
| 17.07.25 | Cantargia Announces Preliminary Topline Efficacy Results From the Phase 2 TRIFOUR Trial of Nadunolimab in Advanced Triple-Negative Breast Cancer | 487 | ACCESS Newswire | LUND, SWEDEN / ACCESS Newswire / July 17, 2025 / Cantargia (STO:CANTA)Nadunolimab added to carboplatin and gemcitabine (GC) did not impact the safety profile of the chemotherapy and was well tolerated... ► Artikel lesen | |
| 16.07.25 | Cantargia Announces Publication of Clinical Data Showing Benefit of Nadunolimab Combination Therapy in Advanced Lung Cancer | 414 | ACCESS Newswire | LUND, SE / ACCESS Newswire / July 16, 2025 / Cantargia (STO:CANTA)Promising efficacy data with median PFS of 7.2 months (95%CI 5.6-9.2), median OS of 13.7 months (95%CI 11.1-18.3), and 1-year survival... ► Artikel lesen |
1 2 3 Weiter >>
52 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 84,60 | -1,34 % | BYD gegen Tesla! KI-Profiteure BioNTech und Rio Tinto Partner Aspermont! Aktien für 2026? | Paukenschlag kurz vor Silvester! BYD hat Tesla vom E-Auto-Thron gestoßen. Die Chinesen sind jetzt auch Weltmarktführer bei rein elektrischen Fahrzeugen. Doch die Aktie hat 2025 klar enttäuscht. Ein... ► Artikel lesen | |
| EVOTEC | 6,338 | +0,76 % | EQS-News: Evotec SE: Evotec ernennt Dr. Sarah Fakih als EVP, Leiterin Global Communications und Investor Relations | EQS-News: Evotec SE
/ Schlagwort(e): Personalie
Evotec ernennt Dr. Sarah Fakih als EVP, Leiterin Global Communications und Investor Relations
01.01.2026 / 07:30 CET/CEST
Für... ► Artikel lesen | |
| QIAGEN | 41,290 | 0,00 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 07.01.2026 | Das Instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON EQUITY wird cum Kapitalmassnahme gehandelt am 07.01.2026 und ex Kapitalmassnahme am 08.01.2026 The instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 694,60 | -0,17 % | Regeneron Just Moved From Underperform To Buy - Here's Why | ||
| BRAIN BIOTECH | 2,650 | -1,49 % | EQS-AFR: BRAIN Biotech AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: BRAIN Biotech AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
BRAIN Biotech AG: Vorabbekanntmachung über... ► Artikel lesen | |
| SCORPIUS | 0,070 | 0,00 % | Tivic Acquires Scorpius Manufacturing Assets And Secures More Than $90 Million Financing | ||
| CARDIOL THERAPEUTICS | 0,879 | +2,21 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
17.12.2025 / 14:38 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen | |
| BURCON NUTRASCIENCE | 1,090 | +4,81 % | Burcon NutraScience Corporation: Burcon Announces Closing of First Tranche of Non-Brokered Private Placement of Convertible Debentures | Vancouver, British Columbia--(Newsfile Corp. - January 2, 2026) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in plant-based... ► Artikel lesen | |
| CSL | 100,12 | +2,86 % | Prediction: CSL shares could soar past $270 in 2026 | ||
| MANNKIND | 5,118 | +2,85 % | MannKind Provides Business Updates and 2026 Growth Drivers | DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 9,736 | -0,61 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Announces Plans to Accelerate NDA Submission Timeline for AXPAXLI in Wet AMD | Ocular intends to submit AXPAXLI New Drug Application (NDA) for wet AMD shortly after year one data from SOL-1, if positive SOL-1 topline data remain on track for 1Q 2026 Ocular plans to leverage... ► Artikel lesen | |
| OXFORD NANOPORE TECHNOLOGIES | 1,626 | -1,93 % | Oxford Nanopore Tech - Upcoming Investor Events and Conferences | ||
| ADAPTIMMUNE THERAPEUTICS | 0,034 | 0,00 % | Adaptimmune Therapeutics PLC: Adaptimmune Announces Changes to Board and Executive Leadership Team | Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 17, 2025) - Adaptimmune Therapeutics plc (OTC Pink: ADAPY) ("Adaptimmune" or the "Company") today announced changes... ► Artikel lesen | |
| CODEXIS | 1,456 | +0,28 % | Codexis Expands Reach of the ECO Synthesis Manufacturing Platform through a Signed Evaluation Agreement with Axolabs for Oligonucleotide Therapeutics | REDWOOD CITY, Calif., Jan. 7, 2026 /PRNewswire/ -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing and Axolabs... ► Artikel lesen | |
| CORMEDIX | 6,450 | -32,81 % | CorMedix, Inc.: CorMedix Therapeutics Announces Leadership and Board Updates | BERKELEY HEIGHTS, N.J., Jan. 08, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening... ► Artikel lesen |
CANTARGIA AB gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +7,74 % bei einem Aktienkurs von 0,418 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CANTARGIA AB finden Sie auf Wallstreet Online.